The FDA came down hard on Novartis, subjecting the company to a public flogging over the data manipulation that, at the end of the day, didn't effect patients' safety. But the issue is too important to give anyone a pass, officials say. “It may sound like we’re kind of bureaucratic paper-pushers, but it’s more than that,” said FDA's Dr. Peter Marks. “It’s making sure that the whole ecosystem understands that when people are working on these things that are highly technically complex, that they have to work truthfully and accurately."

from Kaiser Health News https://ift.tt/2Zj5s3M

Related Posts:

0 comments:

Post a Comment

Popular Posts